Astellas Sues to Block Myrbetriq Copies as New Patent Is Issued

Astellas said copycats of extended-release tablets for the treatment of overactive bladder proposed by generic-drug makers including Novartis’s Sandoz, Teva’s Watson and Aurobindo infringe a patent for Myrbetriq that was issued Tuesday.

• Astellas is seeking a court order blocking copies until the patent has expired, and to collect cash compensation if copies are made before then, according to complaint filed Tuesday in federal court in Wilmington, Delaware
• The U.S. Patent and Trademark Office issued the patent, titled “Pharmaceutical composition for modified release,” on Tuesday, and it will expire in September 2029, complaint says
  • Patent covers the dissolution of ...